IP Library › Assignment 070167/0243
Patent Assignment
Reel/Frame 070167/0243

Security Interest

Recorded: 2025-02-10 Pages: 18
Assignor
OMEGA THERAPEUTICS, INC.
Executed: 2025-02-07
Assignee
PIONEERING MEDICINES 08- B, INC.
55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE, MASSACHUSETTS, 02142
Covered Properties (120)
Methods and Compositions for Modulating Frataxin Expression and Treating Friedrich's Ataxia
Application: 62/904,391 →
Methods and Compositions for Modulating Frataxin Expression and Treating Friedrich's Ataxia
Application: 17/754,051 →
Publication: US 2022/0348893
Compositions and Methods for Modulating Apolipoprotein B (Apob ) Gene Expression
Application: 62/904,325 →
Compositions and Methods for Modulating Apolipoprotein B (Apob) Gene Expression
Application: 17/701,325 →
Publication: US 2022/0288237
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION
Application: 62/904,178 →
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION
Application: 18/637,630 →
Publication: US 2024/0344061
Compositions and Methods for Modulating Forkhead Box P3 (FOXP3) Gene Expression
Application: 62/988,044 →
Compositions and Methods for Modulating Forkhead Box P3 (FOXP3) Gene Expression
Application: 17/929,828 →
Publication: US 2023/0114151
Tissue-Specific Nucleic Acid Delivery by 1,2-Dioleoyl-3-Trimethylammonium-Propane (Dotap) Lipid Nanoparticles
Application: 63/127,812 →
Tissue-Specific Nucleic Acid Delivery by 1,2-Dioleoyl-3-Trimethylammonium-Propane (Dotap) Lipid Nanoparticles
Application: 18/255,906 →
Publication: US 2024/0115730
Tissue-Specific Nucleic Acid Delivery by Mixed Cationic Lipid Particles
Application: 63/178,050 →
Tissue-Specific Nucleic Acid Delivery by Mixed Cationic Lipid Particles
Application: 18/556,563 →
Publication: US 2024/0197636
Compositions and Methods for Modulating Secreted Frizzled Receptor Protein 1 (SFRP1) Gene Expression
Application: 63/219,153 →
Compositions and Methods for Modulating Secreted Frizzled Receptor Protein 1 (SFRP1) Gene Expression
Application: 18/405,286 →
Publication: US 2024/0254462
Lipids for Delivery of Therapeutic Agents
Application: 63/344,162 →
Lipids for Delivery of Therapeutic Agents
Application: 63/380,214 →
Lipids for Delivery of Therapeutic Agents
Application: 18/867,152 →
Title Not Available
Application: 63/655,260 →
Methods for Assessing Dosage for Epigenetic Modifying Agents
Application: 63/539,057 →
Methods for Assessing Dosage for Epigenetic Modifying Agents
Application: 63/599,748 →
Methods for Assessing Dosage for Epigenetic Modifying Agents
Application: 63/574,657 →
Heterocycle Ring Cationic Lipids for Delivery of Therapeutic Agents
Application: 63/378,043 →
Heterocycle Ring Cationic Lipids for Delivery of Therapeutic Agents
Application: 63/380,218 →
Heterocycle Ring Cationic Lipids for Delivery of Therapeutic Agents
Application: 63/380,470 →
Lipid-Like Substituted Aryl and Heteroaryl Compounds as Lipid Nanoparticle (Lnp) Delivery Materials and Therapeutic Uses Thereof
Application: 63/494,871 →
Substituted Piperazine Ionizable Lipids Useful for Therapeutic Lipid Nanoparticle (Lnp) Delivery
Application: 63/494,872 →
Substituted Piperazine Ionizable Lipids Useful for Therapeutic Lipid Nanoparticle (Lnp) Delivery
Application: 63/624,550 →
Methods and Compositions for Modulating PCSK9 Expression
Application: 63/502,590 →
Methods and Compositions for Modulating CTNNB1 Expression
Application: 63/514,488 →
Methods and Compositions for Modulating Methylation of a Target Gene
Application: 63/502,581 →
Remote Patient Monitoring
Application: 63/601,566 →
Aryl and Heteroaryl Lipid Compounds, Lipid Nanoparticle (Lnp) Formulations, and Therapeutic Uses Thereof
Application: 63/624,073 →
Compositions and Methods for Modulating CXCL9, CXCL10, and CXCL11 Gene Expression
Application: 63/468,458 →
Title Not Available
Application: 63/664,585 →
Title Not Available
Application: 63/710,739 →
Title Not Available
Application: 63/643,712 →
Methods and Compositions for Modulating Gene Expression
Application: 62/384,603 →
Methods and Compositions for Modulating Gene Expression
Application: 62/416,501 →
Methods and Compositions for Modulating Gene Expression
Application: 62/439,327 →
Methods and Compositions for Modulating Gene Expression
Application: 62/542,703 →
Methods and Compositions for Modulating Gene Expression
Application: 16/330,999 →
Publication: US 2019/0255106
Methods and Compositions for Modulating Gene Expression
Application: 17/698,912 →
Publication: US 2023/0174978
Methods and Compositions for Modulating Gene Expression
Application: 17/698,917 →
Publication: US 2023/0054672
Compositions and Methods for Cell Delivery
Application: 62/416,367 →
Compositions and Methods for Cell Delivery
Application: 62/416,378 →
Compositions and Methods for Cell Delivery
Application: 62/416,372 →
Compositions and Methods for Modulating Genomic Complex Integrity Index
Application: 62/904,310 →
Compositions and Methods for Modulating Genomic Complex Integrity Index
Application: 17/754,050 →
Publication: US 2022/0267756
Compositions and Methods for Inhibiting Gene Expression
Application: 63/082,555 →
Compositions and Methods for Inhibiting Gene Expression
Application: 18/246,480 →
Publication: US 2023/0399640
Compositions and Methods for Inhibiting Gene Expression
Application: 63/242,957 →
Compositions and Methods for Inhibiting the Expression of Multiple Genes
Application: 63/085,013 →
Compositions and Methods for Inhibiting the Expression of Multiple Genes
Application: 18/028,975 →
Publication: US 2023/0374549
Compositions and Methods for Inhibiting the Expression of Multiple Genes
Application: 63/216,487 →
Compositions and Methods for Modulating Myc Gene Expression
Application: 63/125,833 →
Compositions and Methods for Modulating Myc Expression
Application: 63/137,097 →
Compositions and Methods for Modulating Myc Expression
Application: 18/257,483 →
Publication: US 2024/0132559
Compositions and Methods for Modulating Myc Expression
Application: 63/212,991 →
Compositions and Methods for Modulating Myc Expression
Application: 63/281,022 →
Cxcl-Modulating Compositions and Methods
Application: 18/852,300 →
Publication: US 2025/0195625
Cxcl-Modulating Compositions and Methods
Application: 63/325,524 →
Cxcl-Modulating Compositions and Methods
Application: 63/379,849 →
Cxcl-Modulating Compositions and Methods
Application: 63/478,855 →
Formulations for Modulating Myc Expression
Application: 18/877,408 →
Formulations for Modulating Myc Expression
Application: 63/366,833 →
Formulations for Modulating Myc Expression
Application: 63/377,148 →
Combination Therapies Comprising Myc Modulation
Application: 18/877,552 →
Combination Therapies Comprising Myc Modulation
Application: 63/354,646 →
Combination Therapies Comprising Myc Modulation
Application: 63/489,629 →
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Application: 63/371,970 →
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Application: 63/376,386 →
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Application: 63/481,073 →
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Application: 63/489,633 →
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Application: 63/501,890 →
Kinase Inhibitors and Particles Comprising Myc Modulators
Application: 63/615,073 →
Methods of Editing Dna Methylation
Application: 62/377,520 →
Methods of Editing Dna Methylation
Application: 18/773,428 →
Publication: US 2025/0011744
Regulation of Transcription Through DCAS9-DNMT3A-3L Mediated Methylation of Ctcf Loop Anchors
Application: 62/433,234 →
Regulation of Transcription Through Ctcf Loop Anchors
Application: 16/469,131 →
Publication: US 2020/0149039
Regulation of Transcription Through Ctcf Loop Anchors
Application: 18/329,541 →
Publication: US 2024/0141335
Methods of Altering Gene Expression by Perturbing Transcription Factor Multimers That Structure Regulatory Loops
Application: 62/444,341 →
Methods of Altering Gene Expression by Perturbing Transcription Factor Multimers That Structure Regulatory Loops
Application: 62/596,093 →
Methods of Altering Gene Expression by Perturbing Transcription Factor Multimers That Structure Regulatory Loops
Application: 18/540,829 →
Publication: US 2024/0263184
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4alpha) GENE EXPRESSION
Application: 17/029,820 →
Publication: US 2022/0348908
Methods and Compositions for Modulating Gene Expression
Application: 15/821,632 →
Publication: US 2018/0179525
Methods and Compositions for Modulating Gene Expression
Application: 16/155,688 →
Publication: US 2019/0024086
Compositions and Methods for Cell Delivery
Application: 16/346,684 →
Publication: US 2019/0275104
Compositions and Methods for Cell Delivery
Application: 17/835,659 →
Publication: US 2023/0024896
Methods of Editing Dna Methylation
Application: 16/326,700 →
Publication: US 2019/0359959
Methods of Editing Dna Methylation
Application: 17/858,758 →
Publication: US 2023/0096554
Methods of Altering Gene Expression by Perturbing Transcription Factor Multimers That Structure Regulatory Loops
Application: 16/476,868 →
Publication: US 2019/0352648
Methods and Compositions for Modulating Frataxin Expression and Treating Friedrich's Ataxia
Compositions and Methods for Modulating Apolipoprotein B (Apob) Gene Expression
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4-alpha) GENE EXPRESSION
Compositions and Methods for Modulating Forkhead Box P3 (FOXP3) Gene Expression
Tissue-Specific Nucleic Acid Delivery by 1,2-Dioleoyl-3-Trimethylammonium-Propane (Dotap) Lipid Nanoparticles
Tissue-Specific Nucleic Acid Delivery by Mixed Cationic Lipid Particles
Compositions and Methods for Modulating Secreted Frizzled Receptor Protein 1 (SFRP1) Gene Expression
Lipids for Delivery of Therapeutic Agents
Methods for Assessing Dosage for Epigenetic Modifying Agents
Phospholipids Containing a Heterocycle Ring Having a Tertiary Amine or Amide
Lipids and Lipid-Like Compounds for Therapeutic Lipid Nanoparticle (Lnp) Delivery
Methods and Compositions for Modulating PCSK9 Expression
Methods and Compositions for Modulating CTNNB1 Expression
Methods and Compositions for Modulating Methylation of a Target Gene
Compositions and Methods for Reducing CXCL9, CXCL10, and CXCL11 Gene Expression
Methods and Compositions for Modulating Gene Expression
Compositions and Methods for Cell Delivery
Compositions and Methods for Modulating Genomic Complex Integrity Index
Compositions and Methods for Inhibiting Gene Expression
Compositions and Methods for Inhibiting the Expression of Multiple Genes
Compositions and Methods for Modulation Myc Expression
Cxcl-Modulating Compositions and Methods
Formulations for Modulating Myc Expression
Combination Therapies Comprising Myc Modulation
Combination Therapies Comprising Myc Modulators and Checkpoint Inhibitors
Kinase Inhibitors and Particles Comprising Myc Modulators
Methods of Editing Dna Methylation
Regulation of Transcription Through Ctcf Loop Anchors
Methods of Altering Gene Expression by Perturbing Transcription Factor Multimers That Structure Regulatory Loops
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest May 17, 2017
From: LANDE-DINER, LAURA; BERRY, DAVID ARTHUR
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 042417/0846 →
Assignment of Assignor's Interest May 17, 2017
From: LANDE-DINER, LAURA; BERRY, DAVID ARTHUR
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 042417/0829 →
Assignment of Assignor's Interest Jun 8, 2017
From: LANDE-DINER, LAURA; BERRY, DAVID ARTHUR
To: FLAGSHIP VENTURES MANAGEMENT, INC.
Reel/Frame 042644/0062 →
Change of Name Jun 8, 2017
From: FLAGSHIP VENTURES MANAGEMENT, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 042732/0827 →
Assignment of Assignor's Interest Sep 6, 2017
From: OMEGA THERAPEUTICS, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 043510/0188 →
Assignment of Assignor's Interest Sep 6, 2017
From: LANDE-DINER, LAURA; BERRY, DAVID ARTHUR
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 043510/0206 →
Assignment of Assignor's Interest Sep 6, 2017
From: KARNIK, RAHUL
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 043510/0157 →
Assignment of Assignor's Interest Nov 13, 2018
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS V, INC.
Reel/Frame 047484/0991 →
Assignment of Assignor's Interest Oct 2, 2019
From: LUNARDI, SERENA; SCHEIDEGGER, ADAM WALTER
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 050593/0767 →
Assignment of Assignor's Interest Sep 22, 2020
From: SMITH, JESSE JEROME
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 053844/0287 →
Assignment of Assignor's Interest Sep 23, 2020
From: SMITH, JESSE; KENNEDY, JODI MICHELLE; FARELLI, JEREMIAH D.; GOSS, KENDRICK ALAN
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 053864/0338 →
Assignment of Assignor's Interest Sep 25, 2020
From: SMITH, JESSE JEROME; ASHOK, PATIL VISHWESH; FARELLI, JEREMIAH; KARNIK, RAHUL
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 053880/0023 →
Assignment of Assignor's Interest Jul 27, 2021
From: ASHOK, PATIL VISHWESH; SARISOZEN, CAN; COSTA, DANIEL FERREIRA GOMES
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 056988/0195 →
Assignment of Assignor's Interest Nov 2, 2021
From: ASHOK, PATIL VISHWESH; SARISOZEN, CAN; GIBSON, MARCUS IAN; COSTA, DANIEL FERREIRA GOMES
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 057993/0739 →
Assignment of Assignor's Interest Jan 7, 2022
From: NGUYEN, LAURA ANH; FARELLI, JEREMIAH D.; SCHEIDEGGER, ADAM WALTER; WITT, ABIGAIL ELIZABETH
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 058585/0009 →
Assignment of Assignor's Interest Mar 23, 2022
From: ASHOK, PATIL VISHWESH; FARELLI, JEREMIAH D.; KARNIK, RAHUL; SMITH, JESSE JEROME
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 059373/0545 →
Assignment of Assignor's Interest Mar 24, 2022
From: RAO, TIMSI; KENNEDY, JODI; MANDAL, PANKAJ; FARELLI, JEREMIAH D.
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 059392/0619 →
Corrective Assignment to Correct the the Order of the First Inventor's Name Previously Recorded at Reel: 056987 Frame: 0195. Assignor(S) Hereby Confirms the Assignment. Apr 26, 2022
From: PATIL, VISHWESH ASHOK; SARISOZEN, CAN; COSTA, DANIEL FERREIRA GOMES
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 059794/0294 →
Assignment of Assignor's Interest Jul 18, 2022
From: CHEN, JUSTIN; SULLIVAN, JAMES SCOTT
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 060534/0121 →
Corrective Assignment to Correct the the Second Inventor Name Previously Recorded at Reel: 059373 Frame: 0545. Assignor(S) Hereby Confirms the Assignment. Sep 7, 2022
From: SMITH, JESSE JEROME; PATIL, VISHWESH ASHOK; FARELLI, JEREMIAH D.; KARNIK, RAHUL
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 061390/0263 →
Corrective Assignment to Correct the Inventors Name from Patil Vishwesh Ashok to Vishwesh Ashok Patil Previously Recorded at Reel: 053880 Frame: 0023. Assignor(S) Hereby Confirms the Assignment. Sep 8, 2022
From: SMITH, JESSE JEROME; FARELLI, JEREMIAH D.; KARNIK, RAHUL; SARISOZEN, CAN
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 061391/0600 →
Assignment of Assignor's Interest Feb 14, 2023
From: HU, QI- YING
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 062690/0475 →
Assignment of Assignor's Interest Feb 14, 2023
From: HU, QI- YING
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 062690/0458 →
Assignment of Assignor's Interest Apr 18, 2023
From: HU, QI-YING; WEI, LINLI; NOLASCO, JONATHAN
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 063357/0298 →
Assignment of Assignor's Interest Apr 18, 2023
From: HU, QI-YING; WEI, LINLI; NOLASCO, JONATHAN
To: OMEGA THERAPEUTICS, INC.
Reel/Frame 063357/0197 →